Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

LncRNA KCNQ1OT1 sponges miR-15a to promote immune evasion and malignant progression of prostate cancer via up-regulating PD-L1
Qihua Chen, Bo Li, De-Guo Liu, et al.
Cancer Cell International (2020) Vol. 20, Iss. 1
Open Access | Times Cited: 64

Showing 1-25 of 64 citing articles:

Mechanisms regulating PD-L1 expression in cancers and associated opportunities for novel small-molecule therapeutics
Hirohito Yamaguchi, Jung-Mao Hsu, Wenhao Yang, et al.
Nature Reviews Clinical Oncology (2022) Vol. 19, Iss. 5, pp. 287-305
Closed Access | Times Cited: 331
Molecular Landscape of LncRNAs in Prostate Cancer: A focus on pathways and therapeutic targets for intervention
Sepideh Mirzaei, Mahshid Deldar Abad Paskeh, Elena Okina, et al.
Journal of Experimental & Clinical Cancer Research (2022) Vol. 41, Iss. 1
Open Access | Times Cited: 126
The role of lncRNAs and circRNAs in the PD-1/PD-L1 pathway in cancer immunotherapy
Wenxiao Jiang, Shuya Pan, Xin Chen, et al.
Molecular Cancer (2021) Vol. 20, Iss. 1
Open Access | Times Cited: 120
MicroRNAs as regulators of immune checkpoints in cancer immunotherapy: targeting PD-1/PD-L1 and CTLA-4 pathways
Arefeh Zabeti Touchaei, Sogand Vahidi
Cancer Cell International (2024) Vol. 24, Iss. 1
Open Access | Times Cited: 34
Molecular panorama of therapy resistance in prostate cancer: a pre-clinical and bioinformatics analysis for clinical translation
Milad Ashrafizadeh, Wei Zhang, Yu Tian, et al.
Cancer and Metastasis Reviews (2024) Vol. 43, Iss. 1, pp. 229-260
Closed Access | Times Cited: 17
The roles of PD-1/PD-L1 in the prognosis and immunotherapy of prostate cancer
Yichi Xu, Gendi Song, Shangdan Xie, et al.
Molecular Therapy (2021) Vol. 29, Iss. 6, pp. 1958-1969
Open Access | Times Cited: 80
LncRNA-miRNA axis in tumor progression and therapy response: An emphasis on molecular interactions and therapeutic interventions
Maliheh Entezari, Afshin Taheriazam, Sima Orouei, et al.
Biomedicine & Pharmacotherapy (2022) Vol. 154, pp. 113609-113609
Open Access | Times Cited: 54
Imprinting disorders
Thomas Eggermann, David Monk, Guiomar Pérez de Nanclares, et al.
Nature Reviews Disease Primers (2023) Vol. 9, Iss. 1
Closed Access | Times Cited: 34
STAT3 signaling in prostate cancer progression and therapy resistance: An oncogenic pathway with diverse functions
Mehrdokht Sadrkhanloo, Mahshid Deldar Abad Paskeh, Mehrdad Hashemi, et al.
Biomedicine & Pharmacotherapy (2023) Vol. 158, pp. 114168-114168
Open Access | Times Cited: 28
Recent progress, perspectives, and issues of engineered PD-L1 regulation nano-system to better cure tumor: A review
Zaigang Zhou, Haoxiang Wang, Jie Li, et al.
International Journal of Biological Macromolecules (2023) Vol. 254, pp. 127911-127911
Closed Access | Times Cited: 28
Long Noncoding RNA KCNQ1OT1 is a Prognostic Biomarker and mediates CD8+ T cell exhaustion by regulating CD155 Expression in Colorectal Cancer
Zheng-bin Lin, Long Pei, Zhan Zhao, et al.
International Journal of Biological Sciences (2021) Vol. 17, Iss. 7, pp. 1757-1768
Open Access | Times Cited: 48
KCNQ1OT1: An Oncogenic Long Noncoding RNA
Patrice Cagle, Qi Qi, Suryakant K. Niture, et al.
Biomolecules (2021) Vol. 11, Iss. 11, pp. 1602-1602
Open Access | Times Cited: 48
Importance of long non-coding RNAs in the pathogenesis, diagnosis, and treatment of prostate cancer
Mohammad Taheri, Elham Badrlou, Bashdar Mahmud Hussen, et al.
Frontiers in Oncology (2023) Vol. 13
Open Access | Times Cited: 17
Long non-coding RNAs in cancer: multifaceted roles and potential targets for immunotherapy
Lokesh Kadian, Deepika Verma, Neelam Lohani, et al.
Molecular and Cellular Biochemistry (2024) Vol. 479, Iss. 12, pp. 3229-3254
Closed Access | Times Cited: 8
LncRNA FAM83A-AS1 promotes ESCC progression by regulating miR-214/CDC25B axis
Jinlin Jia, Hongle Li, Jie Chu, et al.
Journal of Cancer (2021) Vol. 12, Iss. 4, pp. 1200-1211
Open Access | Times Cited: 36
LncRNA KCNQ1OT1 Promotes Proliferation, Invasion and Metastasis of Prostate Cancer by Regulating miR-211-5p/CHI3L1 Pathway
Hailong Hao, Huiqing Chen, Liwu Xie, et al.
OncoTargets and Therapy (2021) Vol. Volume 14, pp. 1659-1671
Open Access | Times Cited: 32
Integrated Characterization of lncRNA-Immune Interactions in Prostate Cancer
Wei Hu, Yanru Wang, Zhixiao Fang, et al.
Frontiers in Cell and Developmental Biology (2021) Vol. 9
Open Access | Times Cited: 31
What Do We Have to Know about PD-L1 Expression in Prostate Cancer? A Systematic Literature Review. Part 1: Focus on Immunohistochemical Results with Discussion of Pre-Analytical and Interpretation Variables
Andrea Palicelli, Martina Bonacini, Stefania Croci, et al.
Cells (2021) Vol. 10, Iss. 11, pp. 3166-3166
Open Access | Times Cited: 28
What Do We Have to Know about PD-L1 Expression in Prostate Cancer? A Systematic Literature Review. Part 3: PD-L1, Intracellular Signaling Pathways and Tumor Microenvironment
Andrea Palicelli, Stefania Croci, Alessandra Bisagni, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 22, pp. 12330-12330
Open Access | Times Cited: 28
Exosomal LINC00460/miR-503-5p/ANLN positive feedback loop aggravates pancreatic cancer progression through regulating T cell–mediated cytotoxicity and PD-1 checkpoint
Jun Yao, Ruoyu Gao, Minghan Luo, et al.
Cancer Cell International (2022) Vol. 22, Iss. 1
Open Access | Times Cited: 22
What Do We Have to Know about PD-L1 Expression in Prostate Cancer? A Systematic Literature Review (Part 6): Correlation of PD-L1 Expression with the Status of Mismatch Repair System, BRCA, PTEN, and Other Genes
Andrea Palicelli, Stefania Croci, Alessandra Bisagni, et al.
Biomedicines (2022) Vol. 10, Iss. 2, pp. 236-236
Open Access | Times Cited: 20
Prostate cancer and microRNAs: New insights into apoptosis
Jitendra Gupta, Waleed K. Abdulsahib, Abduladheem Turki Jalil, et al.
Pathology - Research and Practice (2023) Vol. 245, pp. 154436-154436
Closed Access | Times Cited: 11
Cancer‐derived non‐coding RNAs endow tumor microenvironment with immunosuppressive properties
Tong Hu, Run Shi, Yunru Gu, et al.
Wiley Interdisciplinary Reviews - RNA (2023) Vol. 15, Iss. 1
Open Access | Times Cited: 11
Mechanisms and progress of LncRNAs in prostate cancer development and diagnostic therapy
Shihan Zhao, Yuqi Liu, Han Wang, et al.
International Urology and Nephrology (2025)
Closed Access
Glyoxalase-1-Dependent Methylglyoxal Depletion Sustains PD-L1 Expression in Metastatic Prostate Cancer Cells: A Novel Mechanism in Cancer Immunosurveillance Escape and a Potential Novel Target to Overcome PD-L1 Blockade Resistance
Cinzia Antognelli, Martina Mandarano, Enrico Prosperi, et al.
Cancers (2021) Vol. 13, Iss. 12, pp. 2965-2965
Open Access | Times Cited: 21
Page 1 - Next Page

Scroll to top